Gilead Sciences saw its IBD SmartSelect Composite Rating jump to 96 Monday, up from 93 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
The new rating is a sign the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. History shows the top market performers tend to have a 95 or higher score as they launch their major moves.
Gilead Sciences is currently forming a consolidation, with a 119.96 entry. See if the stock can break out in heavy trade at least 40% higher than normal. Keep in mind that it's a later-stage base, and those involve more risk.
One weak spot is the company's 76 EPS Rating, which tracks quarterly and annual earnings growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company posted 0% earnings growth. Sales growth came in at 0%, down from 6% in the previous quarter. The company's next quarterly report is expected on or around Aug. 7.
Gilead Sciences earns the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Harmony Biosciences and Inhibrx Biosciences are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
